CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
CG Oncology (NASDAQ: CGON) said its CEO Arthur Kuan and President Ambaw Bellete will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 PM ET in Boston.
Investors can listen via a live audio webcast on the company website; a replay will be archived for about 90 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – CGON
In the Feb 23 session, CGON gained 1.18%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Clinical timing update | Positive | +29.3% | Moved PIVOT-006 Phase 3 topline data up to 1H 2026. |
| Jan 06 | Investor conference | Neutral | +0.8% | Announced presentation at 44th J.P. Morgan Healthcare Conference. |
| Dec 18 | Research fellowship | Neutral | +1.7% | Launched second NMIBC research fellowship with two $50,000 grants. |
| Dec 05 | Clinical data update | Positive | -3.7% | Reported promising BOND-003 and CORE-008 NMIBC efficacy and safety data. |
| Nov 26 | Board change | Neutral | -1.5% | Added new director and noted BLA initiation for cretostimogene. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical updates have previously seen strong gains, while even favorable data have occasionally met with negative price reactions, suggesting uneven sensitivity to news flow.
Over the past few months, CG Oncology has moved from major clinical and regulatory milestones toward broader investor outreach. On Jan 9, 2026, accelerated timing for PIVOT‑006 Phase 3 topline data in IR NMIBC coincided with a 29.26% gain. Earlier, strong BOND‑003 and CORE‑008 data on Dec 5, 2025 saw a -3.67% move, showing that even promising data did not guarantee a positive reaction. The new TD Cowen conference appearance follows a similar investor-focused event at the J.P. Morgan conference on Jan 15, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 3:10 pm ET. The conference is taking place at the Boston Marriott Copley Place in Boston, MA.
Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com
